© Reuters. Archive image. Four vials with Novavax’s “Nuvaxovid” COVID-19 vaccine in Saabruecken, Germany. February 26, 2022. REUTERS/Frank Simon
Sept 21 (Reuters) – The European Medicines Agency (EMA) expects to make a decision on Novavax’s updated COVID vaccine in October, its director Emer Cooke said on Thursday.
The agency began its evaluation on August 24 and the vaccine was still in the review phase, Cooke said at a press conference.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) will discuss the vaccine at its October meeting, at which the agency “should have a result”, he added.
Novavax’s protein vaccine is also under review by the US Food and Drug Administration (FDA).
(Reporting by Bhanvi Satija in Bengaluru. Editing in Spanish by Javier Leira)
2023-09-21 14:06:00
#Europe #expects #decision #Novavax #COVID #vaccine #October #Reuters
